TScan Therapeutics
  • About
    • Our Company
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners

    About TScan

    TScan is a clinical-stage biopharmaceutical company dedicated to changing lives by discovering new cancer targets and developing safe and effective T cell therapies for patients.

  • Technology
    • Our Approach
    • TargetScan
    • ReceptorScan
    • SafetyScan
    • T-Integrate Cell Engineering
    • Publications

    Technology

    TScan’s therapeutic approach is based on the central premise that we can learn from patients who are winning their fight against cancer in order to treat those who are not.

  • Investors and Media
  • Pipeline
  • Careers
  • For Patients
    • Patient Overview
    • Hematologic Malignancies
    • Solid Tumors
    • Expanded Access Policy

  • About
    • Our Company
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners
  • Technology
    • Our Approach
    • TargetScan
    • ReceptorScan
    • SafetyScan
    • T-Integrate Cell Engineering
    • Publications
  • Investors and Media
  • Pipeline
  • Careers
  • For Patients
    • Patient Overview
    • Hematologic Malignancies
    • Solid Tumors
    • Expanded Access Policy

About

Leadership

  • Management
  • Board of Directors
  • Advisory Board

Stephen Biggar, M.D., Ph.D.

Partner at Baker Bros. Advisors LP

Katina Dorton, J.D., M.B.A.

CFO of Nodthera

Gabriela Gruia, M.D.

Chief Development Officer at Ichnos Sciences

Barbara Klencke, M.D.

Former Chief Medical Officer and Chief Development Officer of Sierra Oncology Inc.

Gavin MacBeath, Ph.D.

CEO of TSCAN

Garry Nicholson

Former President of Pfizer Oncology

R. Keith Woods

Former Chief Operating Officer of argenx

Interested in joining our team? Explore Careers

©2025 TScan Therapeutics
  • Contact
  • Cookie Settings
  • Privacy policy
  • Terms and conditions